Premium
Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma
Author(s) -
Lang Shona H.,
Hyde Catherine,
Reid Ian N.,
Hitchcock Ian S.,
Hart Claire A.,
Gordon Bryden A. A.,
Villette JeanMarie,
Stower Michael J.,
Maitland Norman J.
Publication year - 2002
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10088
Subject(s) - vimentin , pathology , prostate cancer , prostate , cancer research , cd44 , biology , immunohistochemistry , neuroendocrine differentiation , medicine , cancer , cell , genetics
BACKGROUND The metastatic potential of a series of prostate cell lines was analysed by measuring motility and invasiveness, and further correlated to the expression of epithelial differentiation markers. METHODS Invasion and motility were measured using in vitro assays. Immunohistochemistry of cell lines and tissues was used to identify expression of cytokeratins 8 and 1, 5, 10, 14, vimentin, prostate specific antigen, prostate specific membrane antigen, androgen receptor, desmoglein, E‐cadherin, β1 integrin, CD44, hmet, vinculin and actin. RESULTS Expression of vimentin was the only marker to correlate with motility, no markers correlated to invasion. Lower vimentin expression was observed in cells with low motility (PNT2‐C2) and high expression in cells with high motility (P4E6, PNT1a, PC‐3). Vimentin expression was not detected in well differentiated tumours, moderately differentiated tumours contained vimentin positive cells (1/9 bone scan negative, 2/5 bone scan positive), but the majority of poorly differentiated cancers (4/11 bone scan negative, 9/14 bone scan positive) and bone metastases (7/8) had high vimentin expression in tumour cells. CONCLUSIONS Motile prostate cancer cell lines express vimentin. In tissue sections, the presence of vimentin positive tumour cells correlated positively to poorly differentiated cancers and the presence of bone metastases. Prostate 52: 253–263, 2002. © 2002 Wiley‐Liss, Inc.